Skip to content
Screener

Bio-Rad Laboratories BIO Clinical Diagnostics — Goodwill

Other segment segments

Life Science
$490.5M+47.2%

Similar metrics at other companies

Danaher logo
DHRDiagnostics — Goodwill
$11.91B+70.8%
Opko Health logo
OPKDiagnostics — Goodwill
$163.44M0.0%
Labcorp Holdings logo
LHDiagnostics — Goodwill
$5.61B
Revvity logo
RVTYDiagnostics — Goodwill
$1.86B-4.0%
SRT
SRTAClinical — Goodwill
$73.05M
Thermo Fisher Scientific logo
TMOSpecialty Diagnostics — Goodwill
$5.08B+6.1%

Other financials

Income statement

See full
Revenue$592.1M+1.1%
Gross profit$309.4M+1.1%
Operating income$34.1M+43.9%
Net income-$527.1M-924%
EPS (diluted)-$19.55-954%

Balance sheet

See full
Cash & equivalents$509.0M-2.7%
Total debt$987.3M-28.4%
Total equity$6.9B+2.6%
Total assets$9.8B+2.8%

Cash flow

See full
Operating cash flow$108.1M-16.8%
CapEx$30.0M-12.8%
Free cash flow$78.1M-18.2%

Valuation

See full
Market cap$9.3B+30.0%
Enterprise value$9.78B+19.3%
P/E55.1×+32.7×
P/S3.6×+0.8×

Profitability

See full
Gross margin51.9%-1.6pp
Operating margin8.8%-3.1pp
Net margin6.5%+3.4pp
FCF margin13.8%-0.2pp

Returns & leverage

See full
Return on equity2.5%+1.3pp
Debt / equity0.1×-0.1×
Current ratio3.2×-2.8×

Where this comes from

Reported directly by Bio-Rad Laboratories in its filing.

Tagged under the XBRL concept us-gaap:GoodwillGross.

The source filing: Bio-Rad Laboratories’s 10-Q, filed April 30, 2026.

Filed
Apr 30, 2026, 4:19 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000012208-26-000035
Balances as of December 31, 2025Life ScienceClinical DiagnosticsTotal
Goodwill$493.2$421.8$915.0
Accumulated impairment losses(41.8)(293.4)(335.2)
Goodwill, net451.4128.4579.8
Foreign currency adjustments(2.7)(2.7)
Period change, net(2.7)(2.7)
Balances as of March 31, 2026
Goodwill490.5421.8912.3
Accumulated impairment losses(41.8)(293.4)(335.2)

Item 1. Financial Statements (Unaudited)

FAQ

What is Bio-Rad Laboratories's clinical diagnostics — goodwill?
Bio-Rad Laboratories (BIO) reported clinical diagnostics — goodwill of $421.8M in Q1 2026.
How has Bio-Rad Laboratories's clinical diagnostics — goodwill changed year-over-year?
Bio-Rad Laboratories's clinical diagnostics — goodwill increased by 1.3% year-over-year, from $416.5M to $421.8M.
What is the long-term trend for Bio-Rad Laboratories's clinical diagnostics — goodwill?
Over 4 years (2021 to 2025), Bio-Rad Laboratories's clinical diagnostics — goodwill has grown at a 4.7% compound annual growth rate (CAGR), from $1.4B to $1.68B.
What does clinical diagnostics — goodwill mean?
Represents the total carrying value of goodwill specifically allocated to the Clinical Diagnostics business segment. This asset arises when the purchase price of an acquired business in this segment exceeds the fair value of its identifiable net assets.

Ask your AI about Bio-Rad Laboratories's clinical diagnostics — goodwill.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude